Navigation Links
Favrille in Medical News

New Report Just Published: World Multiple Myeloma Therapeutics Market Report

...g Agreement with Seattle Genetics II-51 Celgene Agrees to Acquisition of Pharmion II-51 PerkinElmer Plans Acquisition of ViaCell II-51 favrille Announces Acquisition of Monoclonal Antibody Range from Diversa II-52 Johnson & Johnson Secures Contract worth US$112 Million II-52 Bi...

MyMedicalRecords, Inc. and Favrille, Inc. Close Merger

... needs." "We believe that the combination of favrille and MMR offers our creditors and stockholders the ..." Merger Overview For legal purposes, favrille is acquiring MMR although the combination will be ...ses. As consideration in the business combination, favrille has issued (or reserved for issuance) 92,599,196 s...

Favrille and MyMedicalRecords.com, Inc. Announce Merger Agreement

...21LOGO ) "We believe that the proposed merger of favrille and MMR is consistent with our objective of offeri...ere in the world. We believe this transaction with favrille will give MMR broader access to the investment com...saction Under the terms of the merger agreement, favrille will acquire all of the capital stock of MMR, in a...

Favrille Announces Listing on OTC Bulletin Board

...le's filings with the Securities and Exchange Commission. All forward-looking statements are qualified in their entirety by this cautionary statement. favrille is providing this information as of the date of this release and, except as required by law, does not undertake any obligation to update any forward-l...

Favrille to Report New Data on FavId (Now Specifid) at American Society of Hematology Annual Meeting

.... About the Phase 3 Clinical Trial of Specifid favrille initiated a pivotal, double-blind, placebo control... from the U.S. Food and Drug Administration (FDA). favrille has also received Fast Track designation from the ...ed in their entirety by this cautionary statement. favrille is providing this information as of the date of th...
Favrille in Medical Technology

Favrille Announces Data Cutoff for Phase 3 Registration Trial of Specifid; Data Analysis and Unblinding Expected in June

...mation and prepare for the analysis and unblinding of the trial in June." favrille initiated its Phase 3 randomized, placebo-controlled, double-blind registra...ng statements are qualified in their entirety by this cautionary statement. favrille is providing this information as of the date of this release and, except as...

Favrille Provides Update on Timing of Analysis from Pivotal Phase 3 Clinical Trial; Reports Third Quarter 2007 Financial Results

...Based in part on the guidance provided by the DMB, favrille has determined April 2008 to be the appropriate ti...se 3 trial." Third Quarter 2007 Financial Review favrille also reported its financial results for the third ...f 2008." Conference Call and Webcast Information favrille management will host a conference call today to di...

Favrille Announces Results From Study Showing Enhanced Activity From Insect Cell-Derived Immunotherapy for Lymphoma

...ient-specific, Id/KLH active immunotherapy for the treatment of B-cell NHL. favrille completed enrollment in its pivotal Phase 3 clinical trial of FavId followi...ng statements are qualified in their entirety by this cautionary statement. favrille is providing this information as of the date of this release and, except as...

Favrille Announces Data From Phase 2 Clinical Trial of FavId for Indolent B-Cell Non-Hodgkin's Lymphoma in Europe

...ient-specific, Id/KLH active immunotherapy for the treatment of B-cell NHL. favrille completed enrollment in its pivotal Phase 3 clinical trial of FavId followi...ng statements are qualified in their entirety by this cautionary statement. favrille is providing this information as of the date of this release and, except as...
Favrille in Biological Technology

Favrille and MyMedicalRecords.com, Inc. Obtain Shareholder Approval to Move Forward With Merger

...521LOGO ) "We are pleased to announce that favrille creditors holding more than 85% of the dollar valu...merger is subject to customary closing conditions, favrille meeting certain minimum cash requirements as of cl...and Where to Find It On November 13, 2008, favrille filed a Current Report on Form 8-K with the SEC th...

Favrille Announces Execution of Non-binding Term Sheet for a Merger Transaction

...on-binding term sheet for a reverse merger whereby favrille would acquire all of the capital stock of a privat...f MMR would own approximately 64% of the equity of favrille on a fully diluted basis. The existing equity holders of favrille would own approximately 29% of the Company. Approx...

Favrille Announces Receipt of Nasdaq Letters

...w the minimum $1.00 per share requirement and (ii) favrille has not maintained the $5,000,000 minimum market v...y. In accordance with Marketplace Rule 4450(e)(1), favrille has 90 calendar days, or until October 7, 2008, to...e with the minimum $1.00 per share requirement. If favrille does not regain compliance with either of the abov...

Favrille Announces Resolution of Debt Obligations and Plans for Maximizing Assets

...ll all unneeded fixed assets in the near future. favrille is currently in discussions with its landlord rega... options. The management and board of directors of favrille remain committed to addressing these issues and ma...ed in their entirety by this cautionary statement. favrille is providing this information as of the date of th...

Favrille Announces Workforce Reduction

...le's filings with the Securities and Exchange Commission. All forward-looking statements are qualified in their entirety by this cautionary statement. favrille is providing this information as of the date of this release and, except as required by law, does not undertake any obligation to update any forward-l...

Favrille Announces Results from Phase 3 Registration Trial of Specifid in Patients with Follicular B-Cell Non-Hodgkin's Lymphoma

...for their support and dedication." About the Phase 3 Registration Trial favrille initiated its Phase 3 randomized, placebo-controlled, double-blind registra...ng statements are qualified in their entirety by this cautionary statement. favrille is providing this information as of the date of this release and, except as...

Favrille Reports First Quarter 2008 Financial Results

...the first quarter of 2007. As of March 31, 2008, favrille had cash, cash equivalents and short-term investme...ng options." Phase 3 Registration Trial Update favrille reached the data cutoff date for its Phase 3 regis...trial. Conference Call and Webcast Information favrille management will host a conference call today to di...

Favrille Reports Fourth Quarter and Year End 2007 Financial Results

...e same periods in 2006. As of December 31, 2007, favrille had cash, cash equivalents and short-term investme...rille. Conference Call and Webcast Information favrille management will host a conference call today to di...ed in their entirety by this cautionary statement. favrille is providing this information as of the date of th...

Favrille Announces $21.1 Million Registered Direct Offering

...cal trials of longer duration in more patients are known. All forward-looking statements are qualified in their entirety by this cautionary statement. favrille is providing this information as of the date of this release and, except as required by law, does not undertake any obligation to update any forward-l...

Favrille to Present at BIO InvestorForum

...held at the Palace Hotel in San Francisco. (Logo: http://www.newscom.com/cgi-bin/prnh/20031013/LAM095LOGO ) Ms. Seymour will provide an overview of favrille and the clinical trials of its lead compound, FavId(R), which is currently in a pivotal Phase 3 clinical trial for the treatment of follicular B-cell ...
Other Tags
(Date:9/1/2015)... ... 01, 2015 , ... OncLive® today announced it ... & World Report, to provide breaking news and information about the hospital’s pioneering ... OncLive, which provides oncologists resources and information?they need to deliver the best care ...
(Date:9/1/2015)... ... 2015 , ... The Jerry Segal Classic to benefit the patients of Magee ... Club in Lafayette Hill, PA. Over the past 26 years, the Classic, organized by ... services designed to support patients and their families during their time at Magee Rehabilitation ...
(Date:9/1/2015)... ... September 01, 2015 , ... With former IBMers among ... Math) disciplines since its inception more than 35 years ago. A pilot program begun ... their teachers - and, not just those intent on pursuing careers in these fields. ...
(Date:9/1/2015)... Boston, MA (PRWEB) , ... September 01, 2015 ... ... solutions, today announced the release of version 5.2 of the FirstSpirit Content Management ... Content Cloud initiative. With the new version of FirstSpirit, companies will be well ...
(Date:9/1/2015)... ... 2015 , ... Zecurion, a leading developer of data loss prevention solutions, announced ... DLP developed specifically for Mac OS. , In June 2015, the company successfully completed ... security professionals had participated. The beta test done by the developer community enabled Zecurion ...
Breaking Medicine News(10 mins):Health News:OncLive® and Cleveland Clinic Team up to Provide News, Information About Cancer Research and Patient Care 2Health News:OncLive® and Cleveland Clinic Team up to Provide News, Information About Cancer Research and Patient Care 3Health News:The 26th Jerry Segal Classic Returns to Benefit Patients of Magee Rehabilitation Hospital 2Health News:The 26th Jerry Segal Classic Returns to Benefit Patients of Magee Rehabilitation Hospital 3Health News:Inmar Announces Program to Fuel Student Passion for STEM – with an Unconventional Twist 2Health News:e-Spirit boosts Corporate Content Cloud initiative with release of FirstSpirit 5.2 2Health News:e-Spirit boosts Corporate Content Cloud initiative with release of FirstSpirit 5.2 3Health News:Zecurion Announces Endpoint Security for Mac 2
(Date:8/12/2015)... , Aug. 12, 2015   MedNet Solutions ... the entire spectrum of clinical research, is proud to ... the company,s comprehensive SaaS-based eClinical technology platform, has led ... the first two quarters of 2015.   Q2 2015 ... largest quarters measured by contract value sold in the ...
(Date:8/10/2015)... BOSTON and TELTOW, Germany ... SensoMotoric Instruments (SMI), a world leader in Eye ... the completion of its OEM Eye Tracking Platform for ... Eye Tracking Platform contains reference designs for seamless integration ... kiosk systems, virtual reality HMDs and augmented reality smart ...
(Date:8/5/2015)... , August 5, 2015 According ... Access Management Market by Software, Services, Vertical (BFSI, Airport, IT ... Geography - Global Forecast to 2020", published by MarketsandMarkets, ... Market globally into various segments. The global PIAM Market ... to $546.2 Million by 2019, at a CAGR of ...
Breaking Biology News(10 mins):MedNet Solutions Experiences Explosive Corporate Growth 2SMI Completes OEM Eye Tracking Platform to Cover All Consumer Displays 2SMI Completes OEM Eye Tracking Platform to Cover All Consumer Displays 3Physical Identity and Access Management Market Worth $546.2 Million by 2019 2Physical Identity and Access Management Market Worth $546.2 Million by 2019 3Physical Identity and Access Management Market Worth $546.2 Million by 2019 4
Other Contents